The use of variations in proteomes to predict, prevent, and personalize treatment for clinically nonfunctional pituitary adenomas

EPMA Journal

Volumn 1, Issue 3, 2010, Pages 439-459

  Zhan, Xianquan ^a   Desiderio, Dominic M ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

Author keywords

Clinical nonfunctional pituitary adenoma; Interventional prevention; Personalized patient treatment; Predictive diagnosis; Proteomic variation; Tumor progression monitoring

Indexed keywords

BIOLOGICAL MARKER; GROWTH HORMONE; MITOGEN ACTIVATED PROTEIN KINASE; PROLACTIN; PROTEASOME INHIBITOR; PROTEOME; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; TYROSINE;

APOPTOSIS; BLINDNESS; BLOOD SAMPLING; BREAST CANCER; CANCER DIAGNOSIS; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CEREBROSPINAL FLUID; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME REGULATION; GENETIC HETEROGENEITY; HUMAN; HYPOPHYSIS TUMOR; MASS SPECTROMETRY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NITRATION; NONFUNCTIONING PITUITARY ADENOMA; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PEPTIDOMICS; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN MICROARRAY; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 79953032955     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-010-0028-z     Document Type: Review

References (96)

1. Moreno CS, Evans CO, Zhan X, Okor M, Desiderio DM, Oyesiku NM. Novel molecular signaling in human clinically non-functional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res. 2005; 65: 10214-22.
2. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab. 1990; 71: 1427-33.
3. Alexander JM, Biler BM, Bikkal H, Zervas NT, Arnold A, Klibanski A. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest. 1990; 86: 336-40.
4. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest. 2003; 112: 1603-16018.
5. Zhan X, Desiderio DM. Comparative proteomics analysis of human pituitary adenomas: current status and future perspectives. Mass Spectrom Rev. 2005; 24: 783-813.
6. Zhan X, Desiderio DM. Differences in the spatial and quantitative reproducibility between two second-dimension gel electrophoresis systems. Electrophoresis. 2003; 24: 1834-46.
7. Zhan X, Desiderio DM. Spot volume versus amount of protein loaded onto a gel. A detailed, statistical comparison of two gel electrophoresis systems. Electrophoresis. 2003; 24: 1818-33.
8. Zhan X, Desiderio DM. A reference map of a pituitary adenoma proteome. Proteomics. 2003; 3: 699-713.
9. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis. 1997; 18: 2071-7.
10. Tonge R, Shaw J, Middleton B, Rowlinson E, Currie I, Davison M. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics. 2001; 1: 377-96.
11. Zhou G, Li H, DeCamp D, Chen S, Shu H, Gong Y, et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics. 2002; 1: 117-24.
12. Wolters DA, Washburn MP, Yates III JR. An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem. 2001; 73: 5683-90.
13. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003; 422: 198-207.
14. MacCoss MJ, McDonald WH, Saraf A, Sadygov R, Clark JM, Tasto JJ, et al. Shotgun identification of protein modifications from protein complexes and lens tissue. Proc Natl Acad Sci USA. 2002; 99: 7900-5.
15. Regnier FE, Rigs L, Zhang R, Xiong L, Liu P, Chakraborty A, et al. Comparative proteomics based on stable isotope labeling and affinity selection. J Mass Spectrom. 2002; 37: 133-45.
16. Smolka MB, Zhou H, Purkayastha S, Aebersold R. Optimization of the isotope-coded affinity tag-labeling procedure for quantitative proteome analysis. Anal Biochem. 2001; 297: 25-31.
17. Zhu H, Pan S, Gu S, Bradbury EM, Chen X. Amino acid residue specific stable isotope labeling for quantitative proteomics. Rapid Commun Mass Spectrum. 2002; 16: 2115-23.
18. Gu S, Pan S, Bradbury EM, Chen X. Precise peptide sequencing and protein identification in the human proteome through in vivo lysine-specific mass tagging. J Am Soc Mass Spectrom. 2003; 14: 1-7.
19. Casado-Vela J, Martinez-Esteso MJ, Rodriguez E, Borras E, Elortza F, Bru-Martinez R. iTRAQ-based quantitative analysis of protein mixtures with large fold change and dynamic range. Proteomics. 2010; 10: 343-7.
20. Griffin TJ, Xie H, Bandhakavi S, Popko J, Mohan A, Carlis JV, et al. iTRAQ reagent-based quantitative proteomic analysis on a linear ion trap mass spectrometer. J Proteome Res. 2007; 6: 4200-9.
21. Pierce A, Unwin RD, Evans CA, Griffiths S, Carney L, Zhang L, et al. Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. Mol Cell Proteomics. 2008; 7: 853-63.
22. Zhan X, Desiderio DM. Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med Genomics. 2010; 3: 13.
23. Evans CO, Moreno CS, Zhan X, McCabe MT, Vertino PM, Desiderio DM, et al. Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses. Pituitary. 2008; 11: 231-45.
24. Zhan X, Giorgianni F, Desiderio DM. The proteomics analysis of growth hormone isoforms in human pituitary. Proteomics. 2005; 5: 1228-41.
25. Boguszewski CL, Johannsson G, Bengtsson BA, Johansson A, Carlsson B, Carlsson LM. Circulating non-22-kilodalton growth hormone isoforms in acromegalic men before and after transsphenoidal surgery. J Clin Endocr Metab. 1997; 82: 1516-21.
26. Boguszewski CL, Jansson C, Boguszewski MC, Rosberg S, Carlsson B, Albertsson-Wikland K, et al. Increased proportion of circulating non-22-kilodalton growth hormone isoforms in short children: a possible mechanism for growth failure. J Clin Endocr Metab. 1997; 82: 2944-9.
27. Giorgianni F, Beranova-Giorgianni S, Desiderio DM. Identification and characterization of phosphorylated proteins in human pituitary. Proteomics. 2004; 4: 587-98.
28. Gambino GM, Beck-Peccoz P, Borgato S, Faglia G, Spada A, Persani L. Bioactivity and glycosylation of circulating prolactin in various physiological and pathological conditions. Pituitary. 1999; 2: 225-31.
29. Hoffmann T, Penel C, Ronin C. Glycosylation of human prolactin regulates hormone bioactivity and metabolic clearance. J Endocrinol Invest. 1993; 16: 807-16.
30. Hoffmann T, Gunz G, Brue T, Jaquet P, Ronin C. Prolactin isoforms secreted by human prolactinomas. Horm Res. 1992; 38: 164-70.
31. Zhan X, Desiderio DM. Nitroproteins from a human pituitary adenoma tissue discovered with a nitrotyrosine affinity column and tandem mass spectrometry. Anal Biochem. 2006; 354: 279-89.
32. Zhan X, Desiderio DM. The human pituitary nitroproteome: detection of nitrotyrosyl-proteins with two-dimensional Western blotting, and amino acid sequence determination with mass spectrometry. Biochem Biophys Res Commun. 2004; 325: 1180-6.
33. Zhan X, Desiderio DM. Linear ion-trap mass spectrometric characterization of human pituitary nitrotyrosine-containing proteins. Int J Mass Spectrom. 2007; 259: 96-104.
34. Maceykaa M, Payneb SG, Milstienb S, Spiegela S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta. 2002; 1585: 193-201.
35. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science. 2005; 309: 1735-9.
36. Hla T. Dietary factors and immunological consequences. Science. 2005; 309: 1682-3.
37. Tamura T, Lee DH, Osaka F, Fujiwara T, Shin S, Chung CH, et al. Molecular cloning and sequence analysis of cDNAs for Wve major subunits of human proteasomes (multi-catalytic proteinase complexes). Biochem Biophys Acta. 1991; 1089: 95-102.
38. Kristensen P, Johnsen AH, Uerkvitz W, Tanaka K, Hendil KB. Human proteasome subunits from 2-dimensional gels identified by partial sequencing. Biochem Biophys Res Commun. 1994; 205: 1785-9.
39. Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong SE, et al. A mitochondrial protein compendium elucidates complex I disease biology. Cell. 2008; 134: 112-23.
40. Koene S, Smeitink J. Mitochondrial medicine: entering the era of treatment. J Intern Med. 2009; 265: 193-209.
41. Modica-Napolitano JS, Singh KK. Mitochondria as targets for detection and treatment of cancer. Expert Rev Mol Med. 2002; 4: 1-19.
42. Modica-Napolitano JS, Singh KK. Mitochondrial dysfunction in cancer. Mitochondrion. 2004; 4: 755-62.
43. Schapira AH. Mitochondrial dysfunction in neurodegenerative diseases. Neurochem Res. 2008; 33: 2502-9.
44. Ballinger SW. Mitochondrial dysfunction in cardiovascular disease. Free Radic Biol Med. 2005; 38: 1278-95.
45. Anderson CM. Mitochondrial dysfunction in diabetes mellitus. Drug Dev Res. 1999; 46: 67-79.
46. Rabinovich RA, Bastos R, Ardite E, Llinas L, Orozco-Levi M, Gea J, et al. Mitochondrial dysfunction in COPD patients with low body mass index. Eur Respir J. 2007; 29: 643-50.
47. Mabaliraja U, Dinda AK, Kumar S, Roshan R, Gupta P, Sharma SK, et al. Mitochondrial structural changes and dysfunction are associated with experimental allergic asthma. J Immunol. 2008; 181: 3540-8.
48. Halabe Bucay A. The biological significance of cancer: Mitochondria as a cause of cancer and the inhibition of glycolysis with citrate as a cancer treatment. Med Hypotheses. 2007; 69: 826-8.
49. Goebel HH, Schulz F, Rama B. Ultrastructurally abnormal mitochondria in the pituitary oncocytoma. Acta Neurochir. 1980; 51: 195-201.
50. Horoupian DS. Large mitochondria in a pituitary adenoma with hyperprolactinemia. Cancer. 1980; 46: 537-42.
51. Niroi N, Chrousos GP, Kohn B, Lafferty A, Abu-Asab M, Bonat S, et al. Adrenocortical-pitutiary hybrid tumor causing Cushing's syndrome. J Clin Endocrinol Metab. 2001; 86: 2631-7.
52. Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German pituitary tumor registry. Eur J Endocrinol. 2007; 156: 203-16.
53. Garber K. Targeting mitochondria emerges as therapeutic strategy. J Natl Cancer Inst. 2005; 97: 1800-1.
54. Galluzzi L, Larochette N, Zamzami N, Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene. 2006; 25: 4812-30.
55. Modica-Napolitano JS, Kulawiec M, Singh KK. Mitochondria and human cancer. Cur Mol Med. 2007; 7: 121-31.
56. Bell EL, Klimova T, Chandel NS. Targeting the mitochondria for cancer therapy: regulation of hypoxia-inducible factor by mitochondria. Antioxid Redox Signal. 2008; 10: 635-40.
57. Tandon VR, Sharma S, Mahajan A, Bardi GH. Oxidative stress: a novel strategy in cancer treatment. J K Science. 2005; 7: 1-3.
58. Toyokuni S. Molecular mechanisms of oxidative stress-induced carcinogenesis: from epidemiology to oxygenomics. IUBMB Life. 2008; 60: 441-7.
59. Pinilla L, Tena-Sempere M, Aguilar E. Nitric oxide stimulates growth hormone secretion in vitro through a calcium-and cyclic guanosine monophosphate-independent mechanism. Horm Res. 1999; 51: 242-7.
60. Cuttica CM, Giusti M, Bocca L, Sessarego P, De Martini D, Valenti S, et al. Nitric oxide modulates in vivo and in vitro growth hormone release in acromegaly. Neuroendocrinology. 1997; 66: 426-31.
61. Bocca L, Valenti S, Cuttica CM, Spaziante R, Giordano G, Giusti M. Nitric oxide biphasically modulates GH secretion in cultured cells of GH-secreting human pituitary adenomas. Minerva Endocrinol. 2000; 25: 55-9.
62. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006; 160: 1-40.
63. Yates MS, Kensler TW. Chemopreventive promise of targeting the Nrf2 pathway. Drug News Perspect. 2007; 20: 109-17.
64. Lim JH, Kim KM, Kim SW, Hwang O, Choi HJ. Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage. Pharmacol Res. 2008; 57: 325-31.
65. Turner HE, Nagy ZS, Nullivan N, Esiri MM, Wass JAH. Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clin Endocrinol. 2000; 53: 337-44.
66. Musat M, Vax VV, Borboli N, Gueorguiev M, Bonner S, Korbonits M, et al. Cell cycle dysregulation in pituitary oncogenesis. Front Horm Res. 2004; 32: 34-62.
67. Saeger W. Proliferation markers and cell cycle inhibitors in pituitary adenomas. Front Horm Res. 2004; 32: 110-26.
68. Heaney AP. Pituitary tumour pathogenesis. Br Med Bull. 2006; 75-76: 81-97.
69. Farrell WE, Clayton RN. Molecular pathogenesis of pituitary tumors. Front Neuroendocrinol. 2000; 21: 174-98.
70. Yu R, Ren SG, Melmed S. Proteasome inhibitors induce apoptosis in growth hormone-and prolactin-secreting rat pituitary tumor cells. J Endocrinol. 2002; 174: 379-86.
71. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signaling pathways in cancer. Oncogene. 2007; 26: 3279-90.
72. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004; 23: 2838-49.
73. Johnson GL, Lpadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002; 298: 1911-2.
74. English JM, Cobb MH. Pharmcological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002; 23: 40-5.
75. Olson JM, Hallahan AR. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med. 2004; 10: 125-9.
76. Ewing I, Pedder-Smith S, Franchi G, Ruscica M, Emery M, Vax V, et al. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf). 2007; 66: 348-52.
77. Fougner SL, Bollerslev J, Latif F, Hald JK, Lund T, Ramm-Pettersen J, et al. Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. J Clin Endocrinol Metab. 2008; 93: 1211-6.
78. Dekker LJ, Burgers PC, Kros JM, Smitt PA, Luider TM. Peptide profiling of cerebrospinal fluid by mass spectrometry. Expert Rev Proteomics. 2006; 3: 297-309.
79. Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res. 2004; 3: 179-96.
80. Cheng L, Zhou L, Tao L, Zhang M, Cui J, Li Y. SELDI-TOF MS profiling of serum for detection of laryngeal squamous cell carcinoma and the progression to lymph node metastasis. J Cancer Res Clin Oncol. 2008; 134: 769-76.
81. Peticoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002; 359: 572-7.
82. Dekker LJ, Boogerd W, Stockhammer G, Dalebout JC, Siccama I, Zheng P, et al. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol Cell Proteomics. 2005; 4: 1341-9.
83. Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem. 2003; 49: 1272-5.
84. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst. 2004; 96: 353-6.
85. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics. 2004; 3: 367-78.
86. Diamandis EP, van der Merwe DE. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res. 2005; 11: 963-5.
87. Dkker LJ, Dalebout JC, Siccama I, Jenster G, Sillevis-Smitt PA, Luider TM. A new method to analyze matrix-assisted laser desorption/ionization time-of-flight peptide profiling mass spectra. Rapid Commun Mass Spectrom. 2005; 19: 865-70.
88. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem. 2004; 76: 1560-70.
89. Villanueva J, Martorella AJ, Lawlor K, Philip J, Fleisher M, Robbins RJ, et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol Cell Proteomics. 2006; 5: 1840-52.
90. Rosenling T, Slim CL, Christin C, Coulier L, Shi S, Stoop MP, et al. The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF). J Proteome Res. 2009; 8: 5511-22.
91. Kader HA, Tchernev VT, Satyaraj E, Lejnine S, Kotler G, Kingsmore SF, et al. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol. 2005; 100: 414-23.
92. Joos T, Bachmann J. Protein microarrays: potentials and limitations. Front Biosci. 2009; 14: 4376-85.
93. Andresen H, Bier FF. Peptide microarrays for serum antibody diagnostics. Methods Mol Biol. 2009; 509: 123-34.
94. Ray S, Mehta G, Srivastava S. Label-free detection techniques for protein microarrays: prospects, merits and challenges. Proteomics. 2010; 10: 731-48.
95. Zhu H, Bilgin M, Bangham R, Hall D, Casamayor A, Bertone P, et al. Global analysis of protein activities using proteome chips. Science. 2001; 293: 2101-5.
96. Liu Y, Wu J, Yan G, Hou R, Zhuang D, Chen L, et al. Proteomic analysis of prolactinoma cells by immuno-laser capture microdissection combined with online two-dimensional nano-scale liquid chromatography/mass spectrometry. Proteome Sci. 2010; 8: 2.